[¹⁸F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review

Purpose: This review aimed to summarize the available literature on the clinical application of [¹⁸F] FLT PET imaging in primary brain tumours. Methods: A comprehensive search strategy based on Pubmed/Medline, Scopus, Web of Science, Cochrane Library, Google Scholar, and the Embase databases was carried on using the following search string: ('3` Fluorothymidine'/exp OR 'FLT' OR '[81F]-FLT' OR '[¹⁸F] Fluorothymidine') AND ('pet'/exp OR 'pet' OR 'positron emission tomography') AND ('glioma'/exp OR 'glioma' OR 'brain tumour'/exp OR 'brain tumour’). The search was updated till March 2021 and only articles in English and studies investigating the clinical applications of [¹⁸F] FLT PET and PET/CT in primary brain tumours were considered eligible for inclusion. Results: The literature search ultimately yielded 52 studies included in the systematic review, with main results as follows: a) the uptake of [¹⁸F] FLT may guide stereotactic biopsy but does not discriminate between grade II and III glioma. b) [¹⁸F] FLT uptake and texture parameters correlate with overall survival (OS) in newly diagnosed gliomas. c) In patients with recurrent glioma, proliferative volume (PV) and tumour-to-normal brain (T/N) uptake ratio are independent predictors of survival. d) Patients demonstrating response to therapy at [¹⁸F] FLT PET scan show longer OS compared to non-responders. e) [¹⁸F] FLT PET demonstrated good performance in discriminating tumour recurrence from radionecrosis. However, controversial results exist in comparative literature examining the performance of [¹⁸F] FLT vs. other radiotracers in the assessment of recurrence. Conclusion: [¹⁸F] FLT PET imaging has demonstrated potential benefits for grading, diagnostic and prognostic purposes, despite the small sample size studies due to the relatively low availability of the radiotracer.